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 ABSTRACT  
Objective:  Long-term treatment of osteoporosis is required for optimal efficacy, but 
adherence to therapy is suboptimal with daily and weekly oral bisphosphonates. The 
aim of this study was to assess real-world persistence (long-term adherence) with 
weekly alendronate. 
Patients and methods: Persistence data were collected according to World Health 
Organization criteria for the prior month and year for 102 consecutive patients with 
osteoporosis at three outpatient clinics in Croatia.  Persistence was assessed using 
medication possession ratios (MPR).  Adequate persistence was defined as sufficient 
medication supply to ensure antifracture efficacy (MPR ≥80 %). Self-reported 
persistence data were compared with resupply prescription data from primary care 
physicians (PCPs).  The effect of patient age, co-therapy, co-morbidity, and time since 
osteoporosis was diagnosed were evaluated.  
Results: A diagnosis of osteoporosis was established 3.21±1.83 years prior for the 96 
women and 6 men enrolled (mean age 66.92 ± 8.05 years).  During the previous year, 
86.3 % patients reported not missing any tablets.  Age correlated with the number of 
missed tablets, with older patients missing more tablets (p=0.038).  Patients with co-
therapy (p=0.042) missed more tablets.  PCPs reported that 65.7 % of the patients 
were issued prescriptions for 52 tablets.  A total of 68.7% had MPR >80%.  Patients 
with rheumatoid arthritis did not impact MPR (p=0.936).  Previous fractures or 
number of fractures were not associated with persistence (p>0.05).   
Conclusions: In Croatia, persistence was superior with weekly administered 
alendronate than has been reported elsewhere, perhaps due to socio-cultural factors. 
Larger, longitudinal studies are needed to confirm these results.  
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Short Title:  Weekly Alendronate Therapy in Croatia 
Introduction  
Osteoporosis is “clinically silent“ because the patient is typically unaware of bone 
density loss or the change in bone architecture prior to the time a fracture occurs.  
Because osteoporosis has no symptoms, many patients do not accept long-term 
therapy as a necessity.  This is a major obstacle to treatment, because osteoporosis 
medication must be taken as instructed over a long period in order to achieve the full 
benefit.   
 
Adherence rates reported in clinical trials are likely to differ from that in clinical 
practice.  Suboptimal therapeutic adherence is a widespread issue in clinical practice. 
In chronic diseases, the rate of patient non-adherence varies from 20% in asthma to 
71% in arthritis.1  Consistent with other chronic, largely asymptomatic conditions, 
long-term compliance with medication in osteoporosis is generally poor.2  We 
observed anecdotally that patients in Croatia appear to adhere to their once-a week 
alendronate therapy better than published studies might suggest.  This pilot study was 
conducted to evaluate the persistence, defined as long-term adherence, of patients in 
Croatia receiving alendronate on the basis of densitometric evaluation to weekly 
administered alendronate (ALN/70). 
Patients and methods 
Data on persistence (missed tablets of ALN 70 mg/week) for the previous month and 
year were collected for 102 consecutive patients with osteoporosis at three outpatient 
rheumatology clinics according to World Health Organization (WHO) criteria. 
Medication possession ratios (MPR = days of supply/365 days) were used to assess 
medication persistence.  Adequate persistence was defined as sufficient medication 
supply to ensure antifracture efficacy (MPR ≥ 80%). Resupply prescription data were 
obtained from patients’ primary care physicians. The effect of patient age, co-therapy, 
co-morbidity, and time since osteoporosis was diagnosed were also evaluated. 
 
Descriptive statistics, Chi-square test, T-test, Spearman's test and Cramer's V test 
were used to analyze the results. The SPSS ver. 13.0 statistical program was used for 
all statistical analyses. 
Results 
Data were collected for 6 men and 96 women, mean age 66.9  8.05 years, who 
presented at three outpatient rheumatology clinics.  The diagnosis of osteoporosis was 
established a mean of 3.21  1.83 years ago in this population.  Hypertension (38/102) 
and rheumatoid arthritis (36/102) were the most common co-morbidities.  Eighty-one 
patients (79.4%) were receiving concomitant therapy.  Study patients were taking a 
mean of 2.58  2.18 additional drugs daily, with each patient receiving from 1-7 
different drugs, not including alendronate.   
 
Only two patients reported missing 1 or 2 tablets of ALN 70 in the previous month.  
During the previous year, 86.3 % patients reported that they did not miss any tablets. 
The one-year persistence details are presented in Table 1.  Age correlated with 
number of missed tablets, with older patients missing more tablets (Spearman's test 
p=0.038).  Resupply prescription data from primary care physicians showed that 
65.7% of patients were issued prescriptions for all 52 tablets in the previous year.  
According to self-reported persistence data, patients receiving co-therapy had more 
missed tablets (Mann-Whitney test p=0.042), although the number of co-therapies did 
not reach significance (Spearman's Correlation test p=0.192).  Using the more 
objective criterion of issued prescription co-therapies, and including cut-off groups of 
two versus three or more drugs, or no co-therapy versus two or more drugs, did not 
affect the targeted MPR (Chi square test p=0.632, Chi square test p=0.787, t-test 
p=0.279).  While rheumatoid arthritis was one of the most common comorbidities, 
having rheumatoid arthritis did not affect MPR (Cramer's V test p=0.936).  
A negative correlation was found between the time of diagnosis and the start of 
antiresorptive therapy with the number of purchased tablets (Spearman's test p=0.004) 
so that, as expected, the longer the patient were diagnosed to have had osteoporosis 
and the longer they used antiresorptive therapy, the fewer tablets they received.   
 
Thirteen patients had radiological vertebral fractures, 11 had clinical vertebral 
fractures, 3 had hip fractures, and 11 had any other fracture.  Neither the occurrence 
of previous fractures nor number of fractures (spine, hip, or other) was associated 
with persistence (p0.05 in all cases).  
Discussion 
Suboptimal adherence (<80%) is associated with suboptimal outcomes.  Patients with 
osteoporosis and poor adherence tend to have smaller decreases in rate of bone 
turnover,3 lower bone mineral density,3-5 and significantly higher risk of fractures.6  In 
two large surveys of osteoporosis, the mean rate of discontinuation was 19% over 7 
and 14 months, respectively.7,8  Paid claims data from real-world treatment settings 
showed that one-year compliance rates were <25% for different osteoporosis 
therapies, including bisphosphonates, raloxifene, estrogen, and estrogen plus 
progestin.9   
 
In our study, 86% of patients reported that they had not missed any tablets, and 65% 
were issued prescriptions for all 52 tablets.  These percentages are higher than in the 
study by Recker et al. where adherence for weekly regimens was 55%, or in another 
study, based on administrative claims from 30 health plans in the U.S., which reported 
44.2% persistence.11, 12  Even lower adherence was reported in a study based on 
prescription data from U.S. pharmacies over one year, where only 30% of women 
new to weekly oral bisphosphonate therapy had prescriptions filled covering  about 
three-quarters of the year (271 days); 68.7% had MPR >80%.13  Cramer et al. found 
MPR of 69.2% for once-weekly bisphosphonates users, with dosing frequency the 
strongest predictor of discontinuation time.12  In our study, those with longer-standing 
antiresorptive treatment purchased fewer tablets, but co-therapy and co-morbidity did 
not affect the targeted MPR ≥80%.   
 
One could presume that patients with previous fracture would be more aware of the 
importance of consistently taking the prescribed therapy.  It is interesting that neither 
previous fracture occurrence nor number of fractures were associated with persistence 
in our study.  This result may be due to the small number of patients with fractures. 
Patient non-compliance and non-persistence with chronic therapy are costly. 
Compliant patients use fewer physician services, hospital outpatient services, and 
hospital care.9  The prescribed number of doses per day is inversely related to 
compliance, i.e. less frequent dosing regimens result in better compliance across a 
variety of therapeutic classes.10  This is true with antiresorptive therapy, too. Patients 
taking weekly administered bisphophonates have significantly better compliance and 
adherence than those taking more frequent, daily doses, but it is still suboptimal.11, 12  
The cost of antiresorptive therapy was reimbursed to all patients with established 
osteoporosis by the public health care system in Croatia; cost should therefore not 
have influenced the results. Strong support, and awareness for osteoporosis through 
activities of professional association and non-profitable patients’ associations might 
have played the role in relatively better persistence of antiresorptive treatment in 
Croatia . Moreover, although we found no study that specifically look into it, we feel 
that there is considerable amount of trust in doctors and treatment they offer to their 
patients in Croatia, partly due to traditionally rather high and in general equally 
distributed level of health standard.    
In conclusion, we conducted a study on persistence of weekly-administered 
alendronate in a small cohort of consecutive patients with osteoporosis who were 
treated in three outpatient clinics for rheumatology.  In Croatia, the patients’ 
persistence with weekly administered alendronate is better than the persistence 
recorded in other countries.  Socio-cultural factors could play a role in the results.  
Larger, longitudinal studies are needed to confirm or contradict these results.  
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Table 1. Number of missed tablets of alendronate 70 mg in the previous year 
(n=102). 
 
 No. of missed tablets 
No. of 
patients  
% of 
patients  
Cumulative % 
of patients 
 0 tablets 88 86.3 86.3
 1 tablets  2 2.0 88.2
 2 tablets  5 4.9 93.1
 3 tablets  3 2.9 96.1
 4 tablets  2 2.0 98.0
 12 tablets  1 1.0 99.0
 15 tablets 1 1.0 100.0
 Total 102 100.0  
 
 
